Facebook
Twitter
LinkedIn
ForwardRecorded Presentations from the NCCN 2025 Oncology Fellows Program: New Horizons in Quality Cancer Care™
The goal of this activity is to ensure that oncology fellows, as members of the interprofessional oncology care team, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with cancer.
Target Audience
This program is designed to meet the educational needs of physicians, nurses, PAs, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this program, participants should be able to:
Overall Learning Objectives
• Evaluate advances in the treatment of patients with cancer and key updates in the NCCN Guidelines and apply appropriate treatment and supportive care strategies to optimize patient education and care.
• Review issues related to the following topics: Setting Up for Success: A How-To Guide for Life After Fellowship; Charting Your Course: An Overview of Diverse Career Paths in Oncology; The Spectrum of End-of-Life Care; Exploring New Frontiers in Cancer Treatment: The Expanded Role of Cellular Therapies; and The Room Where It Happens: A Behind the Scenes Look at the NCCN Guidelines Development Process
Setting Up for Success: A How-To Guide for Life After Fellowship
• Identify strategies for achieving success as junior faculty members and describe common obstacles and pitfalls that may be faced in early career.
• Create tailored resumes and CVs that effectively highlight clinical, research, and teaching experience, ensuring competitiveness in both academic and clinical job markets.
• Demonstrate proficiency in interviewing techniques and salary negotiations that will enable fellows to confidently navigate job offers, articulate their value, and secure competitive compensation and contract terms.
Charting Your Course: An Overview of Diverse Career Paths in Oncology
• Identify professional opportunities in the oncology ecosystem that complement a traditional clinical career track.
• Describe how early career oncologists can incorporate non-clinical interests while still meeting the demands of their clinical career and personal life.
• Identify ways in which a trainee can prepare for a variety of career paths during fellowship.
The Spectrum of End-of-Life Care
• Describe interventions that should be addressed during end-of-life care planning for patients with advanced cancer and their caregivers.
• Integrate advanced care planning and end-of-life care practices into a patient’s comprehensive cancer treatment plan.
• Provide clear, consistent, and empathetic communication to patients and their caregivers regarding prognosis and goals of treatment.
Exploring New Frontiers in Cancer Treatment: The Expanded Role of Cellular Therapies
• Describe the existing and emerging cellular therapies in the hematologic malignancies and solid tumor space.
• Understand the benefits and implications of using different types of cellular therapies in the clinic.
• Discuss multidisciplinary strategies to utilize these cell-based therapies and address toxicity in treatment planning.
The Room Where It Happens: A Behind the Scenes Look at the NCCN Guidelines Development Process
• Explain the common considerations and approaches used by NCCN Guidelines panels when updating or developing NCCN Guidelines recommendations.
• Describe how panels apply the NCCN Categories of Evidence and Consensus and the NCCN Categories of Preference to recommendations within NCCN Guidelines.
• Delineate the ways in which NCCN manages conflict of interest and bias among Guidelines panel members.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Michael Constantine, MD
Deborah A. Freedman-Cass, PhD
Katherine L. Harris, MD
Renuka V. Iyer, MD
Wui-Jin Koh, MD
Pallavi Kumar, MD, MPH
Debanjan Pain, MD, MSCE
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Shailender Bhatia, MD
Bristol Myers Squibb: Consulting Fee
Replimune Group Inc.: Consulting Fee
Juskaran S. Chadha, DO
Regeneron Pharmaceuticals, Inc.: Scientific Advisor
Saurin A. Chokshi, MD
Exelixis Inc.: Product/Speakers Bureau; Scientific Advisor
Christopher R. D'Angelo, MD
AbbVie, Inc.: Consulting Fee; Grant/Research Support
BeiGene: Consulting Fee
Bristol Myers Squibb: Consulting Fee; Grant/Research Support
Curis, Inc.: Consulting Fee; Grant/Research Support
Fate Therapeutics: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Genmab: Consulting Fee; Grant/Research Support
Ono Pharmaceutical Co., Ltd.: Consulting Fee
Thomas W. Flaig, MD
Agensys, Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Aurora Oncology: Equity Interest/Stock Options; Intellectual Property Rights
Bristol Myers Squibb: Grant/Research Support
Criterium: Consulting Fee; Scientific Advisor
Genentech, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Merck & Co., Inc.: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support
SeaGen: Grant/Research Support
Timothy Kubal, MD, MBA
Apellis Pharmaceuticals: Scientific Advisor
Alberto S. Pappo, MD
Eli Lilly and Company: Consulting Fee
Merck & Co., Inc.: Consulting Fee
Pfizer Inc.: Consulting Fee
Tara Sanft, MD
Biotheranostics, Inc., A Hologic Company: Honoraria
Lalan S. Wilfong, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee
Genzyme Corporation: Consulting Fee
Pfizer Inc.: Scientific Advisor
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals. Complete accreditation information is provided before each individual educational activity.
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing